Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]

See also

References

  1. ^ a b "Roche – Pipeline". 2014. Archived from the original on 2022-10-23. Retrieved 2014-08-01.
  2. ^ a b "Roche Group Development Pipeline" (PDF). 2014. Archived from the original (PDF) on 2014-08-08. Retrieved 2014-08-01.
  3. ^ "Roche – Pipeline" (PDF). 2015. Archived from the original (PDF) on 2015-05-01. Retrieved 2015-05-14.
  4. ^ Lawrence J (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal. 294 (7854/5).

External links